VM:CC - Voyageur Pharmaceuticals Grants Deferred Share Units

(TheNewswire)

Calgary, Canada – TheNewswire- July 9, 2024 - Voyageur Pharmaceuticals Ltd . ( TSX.V:VM ) ( OTC : VYYRF) ("Voyageur" or the"Corporation") , a provider ofinnovative medical imaging solutions, announces that it has issued435,925 Deferred Share Units ("DSUs") to directors of theCorporation pursuant to its fixed 10% equity incentive compensationplan (the "Plan").  Each DSU represents a right of theholder to receive one common share ("Common Share") of theCorporation effective as of the date that the holder ceases service asa director of the Company. The DSUs are used to compensate directorsof the Corporation for their annual retainers and are issued quarterlyusing a deemed value that is equal to the weighted average share priceduring that quarter. The DSUs do not have an exercise price but inrespect of 435,925 DSUs have a starting value equal to approximately$0.0717 per DSU, based on the weighted average share price for thequarter ended June 30, 2024. The DSUs are subject to the terms of thePlan and the policies of the TSX Venture Exchange (the"Exchange"), and are subject to Exchange approval.  TheDSUs and any Common Shares issued pursuant to the exercise of the DSUsare subject to a four month hold in accordance with the policies ofthe Exchange.

About Voyageur PharmaceuticalsLtd.

Voyageur, a Canadian public company trading under thesymbol VM on the TSX Venture Exchange, is in development of barium andiodine Active Pharmaceutical Ingredients (API) and offershigh-performance, cost-effective imaging contrast agents. With astrategic focus on vertically integrating the barium and iodinecontrast market, Voyageur aims to become a key player by producing itsown barium, iodine, and fullerene minerals.

At the core of its operations, Voyageur owns a 100%interest in the Frances Creek barium sulphate (barite) project. Thisproject boasts exceptional grade minerals suitable for thepharmaceutical marketplace.

Voyageur's business plan is set to generate cash flowby partnering with established third-party GMP pharmaceuticalmanufacturers in Canada, ensuring the validation of its products byregulatory agencies worldwide. As Voyageur solidifies its presence inthe market, it plans to transition into a high-margin domesticmanufacturer of radiology drugs, further expanding its revenuestreams.

Voyageur is committed to sustainability andenvironmental stewardship. Voyageur envisions a future where reducingcarbon emissions is the norm, and to achieve this, it is buildingstate-of-the-art carbon-capture infrastructure utilising the RainCage EDEN TM system . Byinvesting in carbon capture energy sources and sustainablemanufacturing practices, Voyageur aims to generate revenue from carboncaptured “advanced engineered carbon material” which will accelerate its revenue growth. Voyageur's unwavering commitment tothe environment sets it apart as a pioneer in the industry.

Voyageur's ambitious vision is to become the firstvertically integrated company in the radiology contrast media drugmarket. By controlling all primary input costs, from the sourcing ofraw materials to the final production, Voyageur ensures quality andcost efficiency. This approach embodies our motto of "From theEarth to the Bottle," highlighting Voyageur's commitment toresponsible sourcing and manufacturing practices.

For Further Information:

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.

Cautionary Statement Regarding “Forward-Looking”Information

This news release may contain certainforward-looking information and statements, including withoutlimitation, statements pertaining to approval by the Exchange for the DSUgrants, statements relating to Voyageur's business plans, developmentof carbon neutral infrastructure, obtaining carbon neutrality, andother statements pertaining to the business of Voyageur and theperceived benefits to Voyageur from certain business plans . All statementsincluded herein, other than statements of historical fact, areforward-looking information and such information involves variousrisks and uncertainties, including, without limitation, global marketfactors and supply chain issues, risks relating to the regulation andapproval of Voyageur's products, and general risks relating toVoyageur's business. There can be no assurance that such informationwill prove to be accurate, and actual results and future events coulddiffer materially from those anticipated in such information. Adescription of assumptions used to develop such forward-lookinginformation and a description of risk factors that may cause actualresults to differ materially from forward-looking information can befound in the Company's disclosure documents on the SEDAR+ website atwww.sedarplus.ca. Voyageur does not undertake to update anyforward-looking information except in accordance with applicablesecurities laws.

Copyright (c) 2024 TheNewswire - All rights reserved.